Live from the NIH registry
Studies recruiting near Olympia right now
Top 25 of 225 recruiting studies, sorted by proximity — each links to its official registry page
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
N/A
Observational 20,000 participants sought
MultiCare Institute for Research & Innovation — Tacoma, Washington (25.8 mi)
· Sponsor: Heart Rhythm Clinical and Research Solutions, LLC
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Multiple conditions
N/A
Observational 2,900 participants sought
Providence Regional Cancer System-Lacey — Lacey, Washington (3.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Phase 3
Interventional 400 participants sought
Providence Regional Cancer System - Lacey — Lacey, Washington (3.5 mi)
· Sponsor: Pfizer
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy (SMA)
N/A
Observational 700 participants sought
MultiCare Health System — Tacoma, Washington (25.8 mi)
· Sponsor: Novartis Pharmaceuticals
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast Neoplasms, Triple Negative Breast Neoplasms
Phase 3
Interventional 2,400 participants sought
Northwest Medical Specialties, PLLC ( Site 0067) — Tacoma, Washington (25.8 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast Neoplasms, Neoplasm Metastasis
Phase 3
Interventional 800 participants sought
MultiCare Health System — Tacoma, Washington (25.8 mi)
· Sponsor: Eli Lilly and Company
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple Negative Breast Cancer
Phase 3
Interventional 1,514 participants sought
Providence Regional Cancer System — Lacey, Washington (3.5 mi)
· Sponsor: Gilead Sciences
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Phase 3
Interventional 10,000 participants sought
Multicare Health System — Tacoma, Washington (25.8 mi)
· Sponsor: Novo Nordisk A/S
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 3
Interventional 880 participants sought
Providence Regional Cancer System-Lacey — Lacey, Washington (3.5 mi)
· Sponsor: NRG Oncology
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
N/A
Interventional 1,956 participants sought
Providence Regional Cancer System-Lacey — Lacey, Washington (3.5 mi)
· Sponsor: NRG Oncology
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
N/A
Interventional 9,500 participants sought
Saint Clare Hospital — Lakewood, Washington (19.9 mi)
· Sponsor: NRG Oncology
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Mary Bridge Children's Hospital and Health Center — Tacoma, Washington (25.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Hypothyroidism
Phase 2, Phase 3
Interventional 2,800 participants sought
MultiCare Institute for Research & Innovation /ID# 255954 — Tacoma, Washington (25.8 mi)
· Sponsor: AbbVie
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Obesity, Heart Failure
Phase 3
Interventional 5,610 participants sought
CHI Franciscan Research Center — Tacoma, Washington (25.8 mi)
· Sponsor: Novo Nordisk A/S
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Phase 3
Interventional 380 participants sought
Northwest Medical Specialties Tacoma /ID# 276281 — Tacoma, Washington (25.8 mi)
· Sponsor: AbbVie
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Ulcerative Colitis, Crohn's Disease
Phase 3
Interventional 70 participants sought
Multicare Health System Institute for Research and Innovation — Tacoma, Washington (25.8 mi)
· Sponsor: Takeda
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast Cancer, Locally Advanced Breast Cancer
Phase 3
Interventional 1,000 participants sought
Clinical Trial Site — Olympia, Washington (0.4 mi)
· Sponsor: Olema Pharmaceuticals, Inc.
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma, Low Grade Glioma
Phase 3
Interventional 170 participants sought
Mary Bridge Children's Hospital and Health Center — Tacoma, Washington (25.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Phase 3
Interventional 1,350 participants sought
89bio Clinical Study Site — Tacoma, Washington (25.8 mi)
· Sponsor: Hoffmann-La Roche
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 2,400 participants sought
Providence Regional Cancer System-Lacey — Lacey, Washington (3.5 mi)
· Sponsor: SWOG Cancer Research Network
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Phase 2
Interventional 130 participants sought
Northwest Medical Specialties — Tacoma, Washington (25.8 mi)
· Sponsor: Hoffmann-La Roche
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic
Phase 3
Interventional 680 participants sought
American Oncology Network Vista Oncology Division-West office — Olympia, Washington (0.4 mi)
· Sponsor: Pfizer
A Study of YL201 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Phase 1, Phase 2
Interventional 312 participants sought
019 — Tacoma, Washington (25.8 mi)
· Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Metastatic Breast Cancer
Phase 3
Interventional 500 participants sought
Northwest Medical Specialties — Olympia, Washington (0.4 mi)
· Sponsor: American Society of Clinical Oncology
Pan-tumor MRD Study
Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer
N/A
Observational 1,350 participants sought
Northwest Medical Specialties (NWMS) — Tacoma, Washington (25.8 mi)
· Sponsor: Paradigm Health